Response of I_Ca,L to IBMX in WT and AMPKα2-/- mice AVMs. by Anne Garnier (130125)

Subjects:

Response of developed pressure to forskolin and isoprenaline of isolated perfused hearts. by Anne Garnier (130125)

Subjects:

AMPK phosphorylation and AC5 and AC6 gene expression in hearts from WT and AMPKα2-/- mice following TAC. by Anne Garnier (130125)

Subjects:

A systematic review into the: effect of feeding food rich in cyp2a6 and glutathione enzymes on decreasing nicotine level in the body of smokers by Dani Nasirul Haqi (14159056)

Representative examples of LBNP and LBPP/hypoxia experiment. by Marcus Thudium (6441863)

Full-length PRR expression increases and sPRR secretion decreases in the absence of PACE4 in mouse. by Amro H. Mohammad (15081540)

TBEV-induced translational arrest results in the decreased protein levels of GAPDH, HPRT1, and viperin. by Martin Selinger (3195987)

Cycloheximide (CHX) treatment decreases production of rRNA transcripts by POLR1 and POLR3. by Martin Selinger (3195987)

“…<p>(A) DAOY cells were treated with CHX (100 μg/ml) for either 6 or 14 hours; for metabolic RNA labelling, 5-EU was added 2 hours before the sample collection. …”

Real-time measurements of cAMP in response to IBMX in control and AICAR-treated rat AVMs. by Anne Garnier (130125)

Subjects:

The image illustrates the five steps of the experiment. by Deborah Ribeiro Frazão (9188152)

Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

Loss of nsp14-ExoN activity decreases recombination frequency and alters recombination junction patterns across the genome. by Jennifer Gribble (10005444)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: